Increased Cytotoxicity of 2′,2′‐Difluoro‐2′‐Deoxycytidine in Human Leukemic Cell‐Lines After a Preincubation with Cyclopentenyl Cytosine
- 31 December 2004
- journal article
- Published by Taylor & Francis in Nucleosides, Nucleotides and Nucleic Acids
- Vol. 23 (8-9) , 1517-1521
- https://doi.org/10.1081/ncn-200027733
Abstract
The in vitro modulating effect of Cyclopentenyl cytosine (CPEC) on the metabolism of gemcitabine was studied in lymphocytic and myeloid leukemic cell-lines. In MOLT-3 cells, that were pretreated with CPEC, the incorporation of 2',2'-difluoro-2'-deoxycytidine triphosphate (dFdCTP) into DNA was significantly increased by 57-99% in comparison with cells that were only treated with gemcitabine. The increased incorporation of dFdCTP into DNA in CPEC pretreated cells was paralleled by an increase in apoptotic and necrotic cells of 17-34%. In HL-60 cells that were preincubated with CPEC, increased concentrations of the mono-/di- and triphosphate form of gemcitabine were observed, as well as an increased incorporation of dFdCTP into DNA (+773%). This increased incorporation was paralleled by a significant increase in apoptosis and necrosis. We conclude that CPEC enhances the incorporation of dFdCTP into DNA and thus increases the cytotoxicity of gemcitabine in lymphocytic and myeloid leukemic cell-lineKeywords
This publication has 8 references indexed in Scilit:
- Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597Journal of Clinical Oncology, 2003
- Prolonged Infusion of Gemcitabine: Clinical and Pharmacodynamic Studies During a Phase I Trial in Relapsed Acute Myelogenous LeukemiaJournal of Clinical Oncology, 2002
- Cyclopentenyl cytosine increases the phosphorylation and incorporation into DNA of 1‐β‐D‐arabinofuranosyl cytosine in a human T‐lymphoblastic cell lineInternational Journal of Cancer, 2002
- Cyclopentenyl Cytosine Increases the Phosphorylation and Incorporation into DNA of Arabinofu-Ranosyl Cytosine in a Myeloid Leukemic Cell-LineAdvances in experimental medicine and biology, 2002
- Treatment of refractory T‐cell malignancies using gemcitabineBritish Journal of Haematology, 2001
- In vitro inhibition of cytidine triphosphate synthetase activity by cyclopentenyl cytosine in paediatric acute lymphocytic leukaemiaBritish Journal of Haematology, 2000
- Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumorsAnnals of Oncology, 1998
- Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreasInvestigational New Drugs, 1994